PII Launches Drug Delivery Solutions Initiative
PII Launches Drug Delivery Solutions Initiative
January 20th, 2009-PII, (Pharmaceutics International, Inc.) announced today the formal launch of a new business initiative, PII Drug Delivery Solutions. In response to demand from its clients for product development tools that meet the challenges of problematic new chemical entities (NCEs) and of product life cycle management (LCM), PII has put together a strategy and dedicated resources focused on drug delivery. This new initiative, named PII Drug Delivery Solutions builds on the PII’s proven track record in formulation development and pharmaceutical manufacturing to help its clients bring new products to market with optimized clinical profiles and higher commercial value.
Since its inception, PII has built considerable expertise in drug delivery, including conventional controlled release formulation approaches, a portfolio of PII – developed technologies and programs involving third-party platforms-its alliance with Penwest Pharmaceuticals for TIMERx technology being an example.
The strategy for PII Drug Delivery Solutions is to provide dedicated business development, centers of technical excellence, proactive partnering and integrated support from PII core resources. PII believes that its exciting portfolio of in-house and partnered drug delivery technologies can be put to work to assist clients with their product development needs, be they early-stage drug candidate optimization through to the revitalization of a marketed compound.
Steve King, Senior Vice President of PII said, “Our dedicated business development team lead by Robin Mitchell and Susan Wiggins has extensive experience in drug delivery and contract services. We aim to proactively bring creative problem solving solutions and product concepts to our clients. PII already has a very powerful portfolio of technology platforms at our disposal and intends to build on this during 2009.” “PII has quietly developed some impressive technologies of its own-nanoparticle formulations and MedCrystalForms’ mixed phase co-crystals for enhanced drug bioavailability for example. Through our partnerships with companies like Penwest, we can tackle a broad range of controlled release challenges too”, said Robin Mitchell, Senior Director Drug Delivery Solutions adding, “Susan Wiggins and I are very excited about the role that we can play to strengthen our clients’ business success in today’s very competitive markets."
A new website launched today-www.piidds.com-introduces PII Drug Delivery Solutions. The site will feature PII’s growing portfolio of capabilities and resources as it expands.
About Pharmaceutics International, Inc.
PII is a privately held leading multi-national Drug Delivery Solutions company providing services to facilitate drug development with or without patented technologies. The corporate headquarters are located in Hunt Valley Maryland USA with a European facility in Reading, UK. Services range from preformulation, formulation development, manufacture of clinical trial material through to commercial
manufacture. For further information about PII go to: www.piidds.com and www.pharm-int.com
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FOCUS Trial Results Show Solriamfetol Significantly Reduces ADHD Symptoms, Severity in Adults
March 27th 2025Solriamfetol achieved the primary and key secondary endpoint of the Phase III FOCUS trial by significantly lowering attention-deficit hyperactivity disorder symptoms and disease severity in adults compared to placebo, with a favorable safety and tolerability profile.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
